一名获得性免疫缺陷综合征患者血液透析期间齐多夫定的处置情况。
Zidovudine disposition during hemodialysis in a patient with acquired immunodeficiency syndrome.
作者信息
Tartaglione T A, Holeman E, Opheim K, Smith T, Collier A C
机构信息
Department of Pharmacy, University of Washington, Seattle.
出版信息
J Acquir Immune Defic Syndr (1988). 1990;3(1):32-4.
Zidovudine (azidothymidine, AZT) disposition was examined during a hemodialysis session in an HIV-infected male with mesangial proliferative glomerulonephritis. Serum concentrations of zidovudine and its glucuronidated inactive metabolite (G-ZDV) were measured by HPLC. Zidovudine pharmacokinetics were similar to previous reports in patients with normal renal function, however, G-ZDV concentrations were significantly elevated (23-440 times zidovudine concentration). Hemodialysis did not appreciably reduce zidovudine or G-ZDV levels. Significance of chronically elevated G-ZDV levels is unknown.
在一名患有系膜增生性肾小球肾炎的HIV感染男性进行血液透析期间，对齐多夫定（叠氮胸苷，AZT）的处置情况进行了研究。通过高效液相色谱法测定血清中齐多夫定及其葡萄糖醛酸化无活性代谢物（G-ZDV）的浓度。齐多夫定的药代动力学与先前关于肾功能正常患者的报告相似，然而，G-ZDV浓度显著升高（是齐多夫定浓度的23至440倍）。血液透析并未明显降低齐多夫定或G-ZDV水平。G-ZDV水平长期升高的意义尚不清楚。
Zotero 插件